The perpetual lawsuit held between hemostenix and aspire health science has met its end, eventually enabling the company to gain back ultimate possession over its lost intellectual property.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.